Breaking News

NorthStar Medical Cuts Ribbon at New Dose Manufacturing Center in Wis.

The additional facility will play a critical role in the advancement of diagnostic and therapeutic radiopharmaceuticals.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, hosted a grand opening event and ribbon-cutting at the NorthStar Dose Manufacturing Center in Beloit, Wis., on October 3, 2024.
 
NorthStar’s additional facility will play a critical role in the advancement of diagnostic and therapeutic radiopharmaceuticals as the capacity will lead to further options for biopharmaceutical and pharmaceutical companies, and will provide them with customized solutions to help navigate the complexities of radioisotope research, development and manufacturing. The purpose-built design will add much-needed capacity to the industry, and will allow for NorthStar to continue to add more services to meet the demand and regulatory guidelines of customers around the world.
 
“NorthStar has evolved from a one product isotope manufacturer to a company prepared to develop, produce, process and ship a board range of varied pharmaceuticals from one single vertically integrated campus,” said Frank Scholz, President and Chief Executive Officer of NorthStar Medical Radioisotopes. “Important clinical studies are underway using Actinium-225 (Ac-225) and Copper-67 (Cu-67) in patients with various types of cancers, including prostate, lung, breast, colon, lymphoma and neuroendocrine tumors. NorthStar is proud to be at the forefront of making these promising radiopharmaceutical therapies a reality.”
 
Dr. Scholz continued, “With passion and strong dedication to the radiopharmaceutical industry, our entire campus has been purpose-built. It was designed with a focus on redundancy, reliability, quality, scalability, and safety. We will be capable of expanding production as our customer needs increase.”
 
NorthStar is already routinely producing the therapeutic radioisotope Cu-67, and later this year, will become one of the first producers of Ac-225. In addition, this facility will support all phases of the pharmaceutical life cycle for critical medical radioisotopes, including Ac-225, Lu-177, Cu-64, Cu-67, In-111, amongst others, from research and development, clinical phase manufacturing, through to commercial manufacturing.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters